Loading
COLUMBUS tested encorafenib-binimetinib, the third BRAF/MEK doublet, which has the longest median survival of the class and less fever than dabrafenib-trametinib.
COLUMBUS, trial NCT01909453 sponsored by Array, now Pfizer, and reported in 2018, tested encorafenib plus binimetinib, the third BRAF and MEK doublet, in advanced BRAF V600 melanoma against vemurafenib and against encorafenib alone. It randomised 577 patients, met its primary progression-free survival endpoint against vemurafenib with a large effect, and its seven-year update showed the longest median survival of the class, with less fever and photosensitivity than dabrafenib plus trametinib, attributed to encorafenib's longer dissociation half-life on BRAF; approval followed in June 2018. OnCo links it to BRAF as a target, the MAPK pathway, encorafenib, binimetinib, vemurafenib, Paolo A. Ascierto and Reinhard Dummer, and the class effect was replicated in coBRIM and COMBI-d and COMBI-v. Whether the tolerability difference changes which doublet clinicians choose is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
577 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Encorafenib + binimetinib | - | 14.9 months | 0.54 | - | link |
| Vemurafenib | - | 7.3 months |
Encorafenib-binimetinib is one of three standard BRAF-MEK doublets for advanced melanoma and is often chosen for its tolerability.
A second publication from the COLUMBUS trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Shares Paolo A. Ascierto, Test intermittent dosing of targeted drugs to delay resistance, with honest priors, Vemurafenib, BRAF V600-mutant melanoma.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV).
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Melanoma.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), BRAF.
Shares Binimetinib, Encorafenib, BRAF, Pfizer (incl. Seagen).
Shares Vemurafenib, BRAF V600-mutant melanoma, BRAF, Melanoma.
Shares Binimetinib, Vemurafenib, Encorafenib, BRAF V600-mutant melanoma.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, Vemurafenib, BRAF V600-mutant melanoma.